Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

O. V. Sintsova; E. V. Leychenko; I. N. Gladkikh; A. P. Kalinovskii; M. M. Monastyrnaya; E. P. Kozlovskaya

doi:10.1134/S1607672919060097

Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Авторы: Sintsova O.V.¹, Leychenko E.V.¹, Gladkikh I.N.¹, Kalinovskii A.P.¹^,2, Monastyrnaya M.M.¹, Kozlovskaya E.P.¹
Учреждения:
1. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences
2. School of Natural Sciences, Far Eastern Federal University
Выпуск: Том 489, № 1 (2019)
Страницы: 385-387
Раздел: Biochemistry, Biophysics, and Molecular Biology
URL: https://journals.rcsi.science/1607-6729/article/view/213120
DOI: https://doi.org/10.1134/S1607672919060097
ID: 213120

Цитировать

Полный текст

Открытый доступ
Доступ закрыт

Доступ предоставлен
Доступ закрыт

Только для подписчиков

Аннотация
Об авторах
Список литературы
Дополнительные файлы
Статистика

Аннотация

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose^TM or Glucobay^TM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.